



Folic Acid

*Ethylenediamine
EEDQ*



Folate NH₂



(EC), Sulfo-NHS, EDC

2) $\text{Na}^{99\text{m}}\text{TcO}_4 / \text{SnCl}_2$



$^{99\text{m}}\text{Tc}$ -EC-folate




FIG. 1

BEST AVAILABLE COPY




FIG. 4




FIG. 5




FIG. 6A

FIG. 6B




FIG. 7





FIG. 8A






FIG. 9




FIG. 10




FIG. 11A




FIG. 11B




FIG. 12




FIG. 13




FIG. 14A




FIG. 14B




FIG. 15A

***^{99m}Tc -EC-Nitroimidazole (NIM)
(100 μCi /mouse, iv.)***





FIG. 15B


^{99m}Tc-EC-Nitroimidazole (NIM)




15 MIN.



30 MIN.



1 HOUR



2 HOUR


2 HOUR

FIG. 15C

*^{99m}Tc-EC-Nitroimidazole (NIM)
(100 μ Ci/mouse, iv.)*




15 MIN.



30 MIN.




1 HOUR



2 HOUR

FIG. 15D




Synthesis of EC-GAP

FIG. 16




TUMOR

15 MIN.




TUMOR

30 MIN.



TUMOR


1 HOUR



TUMOR


2 HOUR

FIG. 17




30 MIN.

TUMOR




2 HOUR

TUMOR



15 MIN.

TUMOR



1 HOUR

TUMOR

FIG. 18



30 MIN.

TUMOR




2 HOUR

TUMOR



15 MIN.

TUMOR



1 HOUR

TUMOR

FIG. 19A

^{99m}Tc -EC-Annexin V
(100 μCi /mouse, iv.)




FIG. 19B




FIG. 20A




FIG. 20B






FIG. 21




FIG. 22




FIG. 23




FIG. 24




FIG. 25




FIG. 26




FIG. 27




FIG. 28



FIG. 29




FIG. 30




FIG. 31



FIG. 32



FIG. 33




FIG. 34



FIG. 35




FIG. 36




FIG. 37A






FIG. 37B




^1H -NMR of EC.

FIG. 38A



^1H -NMR of neomycin

FIG. 38B



^1H -NMR of EC-neomycin

FIG. 38C




FIG. 39




FIG. 40A




FIG. 40B




FIG. 40C




FIG. 41

^{99m}Tc -EC-NEO




FIG. 42

^{99m}Tc -EC-NEO




FIG. 43

^{18}F -FDG




FIG. 44

^{18}F -FDG




FIG. 45




FIG. 46




FIG. 47





FIG. 48A



AGENT (dose)
FIG. 48B




FIG. 49




FIG. 59




FIG. 50




FIG. 51




FIG. 52





FIG. 53



^{99m}Tc -EC-GAP-Glucosamine

FIG. 54




FIG. 55A






FIG. 55B




TIME
FIG. 55C




TIME

FIG. 56



GLUCOSE DOSAGE
FIG. 57



TIME
FIG. 58




FIG. 60




FIG. 61




FIG. 62




FIG. 63




FIG. 64A




FIG. 64B




FIG. 65




FIG. 66




FIG. 67






FIG. 68




AGENTS

FIG. 69




Glucose Isomer

FIG. 70




Glucose Isomer

FIG. 71



Glucose Isomer

FIG. 72



Glucose Isomer

FIG. 73







FIG. 74





T = Tumor

FIG. 76



ORGANS
FIG. 77




FIG. 78




FIG. 79




FIG. 80






FIG. 81



PRE OP



POST OP

FIG. 82A








FIG. 82B



POST-OP

FIG. 83A

PRE-OP




FIG. 83B




FIG. 84A



FIG. 85A




FIG. 84B





FIG. 85B



PRE RTX



POST RTX



POST RTX



PRE RTX

FIG. 86A



FIG. 86B




FIG. 86C

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.